Soleno Therapeutics (NASDAQ: SLNO) deregisters 3,000,000-share resale after merger

Rhea-AI Filing Summary

Soleno Therapeutics, Inc. files a post-effective amendment to deregister securities previously registered for resale and confirms termination of that registration following its merger into Neurocrine Biosciences.

The amendment states the Registration Statement covering an aggregate of 3,000,000 shares of common stock is being removed from registration and that all unsold or unissued securities under Registration No. 333-275120 are terminated as of May 21, 2026.

Insights

Securities Attorney

Legal correction and deregistration tied to a merger; procedural but important for compliance.

The filing corrects an administrative form-type error and formally deregisters the resale registration for 3,000,000 shares under Registration No. 333-275120. It invokes the Registration Statement undertakings to remove unsold securities upon termination of the offering.

Key dependency: the Merger Agreement dated April 5, 2026 is the operative transaction; refer to the agreement attached as Exhibit 2.1 to the Form 8-K filed on April 6, 2026 for full terms.

Corporate Finance Analyst

Administrative deregistration follows the Merger and ends the registered resale overhang.

The amendment removes the prior resale registration of 3,000,000 shares, stating that after the merger the Registrant became a wholly owned subsidiary of Parent and terminated the offering. This eliminates the registered resale capacity under that filing.

Cash-flow treatment and proceeds disposition are not described in this excerpt; subsequent filings may disclose transaction consideration details.

Key Figures

Registered resale amount: 3,000,000 shares Registration number: 333-275120 Post-effective amendment date: May 21, 2026 +1 more

4 metrics

Registered resale amount 3,000,000 shares aggregate resale registration under Registration No. 333-275120

Registration number 333-275120 Registration Statement being amended and terminated

Post-effective amendment date May 21, 2026 date this Post-Effective Amendment was signed and filed

Merger Agreement date April 5, 2026 date of the Agreement and Plan of Merger cited in the amendment

Key Terms

post-effective amendment, deregister, resale registration

3 terms

post-effective amendment regulatory

"This Post-Effective Amendment No. 1 to the Registration Statement on Form S-3"

A post-effective amendment is an official update to a securities registration document filed after that document has become effective with regulators; it corrects, adds or replaces information about the securities, the company, or an offering. Investors care because it keeps the legal record current and can change what is being sold or the rights attached to shares — like getting a revised product manual after a launch that may affect value or use.

deregister regulatory

"This Post-Effective Amendment is being filed by the Registrant to deregister any and all securities registered but unsold"

Deregister is the act of removing a company’s securities from a public regulatory registry or ending their listing on a stock exchange; think of it like taking a car off public roads so it no longer needs public inspections. For investors, deregistration matters because it usually reduces required public disclosures, can make shares harder to buy or sell, and increases uncertainty about the company’s finances and governance due to lower transparency and liquidity.

resale registration financial

"relating to the registration of a resale of an aggregate of 3,000,000 shares"

Resale registration is the formal filing with securities regulators that allows previously restricted or privately held shares to be sold publicly. Think of it as getting official permission to unlock and list a sealed package of stock so it can be traded openly; that matters to investors because it increases liquidity, can change the number of shares available on the market, and reduces legal risk for sellers, all of which can affect a company’s share price.

As filed with the Securities and Exchange Commission on May 21, 2026

Registration No. 333-275120

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

POST- EFFECTIVE AMENDMENT NO. 1

TO

FORM S-3

REGISTRATION STATEMENT NO. 333-275120

UNDER

THE SECURITIES ACT OF 1933

Soleno Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware		77-0523891
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification Number)

100 Marine Parkway, Suite 400

Redwood City, CA 94065

(650) 213-8444

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

Darin M. Lippoldt

President and Secretary

Soleno Therapeutics, Inc.

6027 Edgewood Bend Court

San Diego, California 92130

(858) 617-7600

(Name, address, including zip code, and telephone number, including area code, of agent for service)

With a copy to:

Jamie Leigh

Kevin Cooper

Carlos Ramirez

Cooley LLP

3 Embarcadero Center, 20th Floor

San Francisco, California 94111

(415) 693-2000

(Approximate date of commencement of proposed sale to the public): Not applicable.

If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box: ☐

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box: ☒

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ☐

If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer		☒		Accelerated filer		☐
Non-accelerated filer		☐		Smaller reporting company		☐
				Emerging growth company		☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

EXPLANATORY NOTE

This Post-Effective Amendment No. 1 (this “Post-Effective Amendment”) to the Registration Statement on Form S-3 (File No. 333-275120) (the “Registration Statement”) of Soleno Therapeutics, Inc. (the “Registrant”) was previously filed with the U.S. Securities and Exchange Commission (the “SEC”) on May 18, 2026; however, due to an administrative error, such filing was incorrectly filed as form type “POSASR” rather than form type “POS AM.” This Post-Effective Amendment is being filed to correct the error. No change is being made to the Post-Effective Amendment No. 1 to the Registration Statement on Form S-3 (File No. 333-276344) that the Registrant filed with the SEC on May 18, 2026 as form type “POSASR.”

DEREGISTRATION OF SECURITIES

This Post-Effective Amendment is being filed by the Registrant to deregister any and all securities registered but unsold or otherwise unissued as of the date hereof under the Registration Statement, as more specifically identified below, previously filed by the Registrant with the SEC:

Registration Statement No. 333-275120, filed with the SEC on October 20, 2023, relating to the registration of a resale of an aggregate of 3,000,000 shares of the Registrant’s common stock, par value $0.001 per share, by the selling stockholders named therein.

On May 18, 2026, pursuant to an Agreement and Plan of Merger (the “Merger Agreement”), dated as of April 5, 2026, by and among the Registrant, Neurocrine Biosciences, Inc. (“Parent”) and Sigma Merger Sub, Inc. (“Merger Sub”), Merger Sub merged with and into the Registrant (the “Merger”), with the Registrant continuing as the surviving corporation and becoming a wholly owned subsidiary of Parent. As a result of the transactions contemplated by the Merger Agreement, the Registrant has terminated any and all offerings and sales of securities pursuant to the Registration Statement. In accordance with the undertakings made by the Registrant in the Registration Statement to remove from registration, by means of a post-effective amendment, any of the securities of the Registrant registered under the Registration Statement which remain unsold at the termination of the offering, the Registrant hereby terminates the effectiveness of the Registration Statement and removes from registration all of the securities that remain unsold under the Registration Statement as of the date hereof, if any. The Registration Statement is hereby amended, as appropriate, to reflect the deregistration of such securities. After giving effect to this Post-Effective Amendment, there will be no remaining securities registered by the Registrant pursuant to the Registration Statement.

The foregoing description of the Merger, the Merger Agreement and the transactions contemplated thereby does not purport to be complete and is subject to, and qualified in its entirety by, the Merger Agreement, which is attached as Exhibit 2.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on April 6, 2026.

SIGNATURE

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused this Post-Effective Amendment to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Diego, State of California on May 21, 2026.

SOLENO THERAPEUTICS, INC.
By:		/s/ Darin M. Lippoldt
		Name: Darin M. Lippoldt
		Title: President and Secretary

No other person is required to sign this Post-Effective Amendment in reliance upon Rule 478 under the Securities Act of 1933, as amended.

FAQ

What did Soleno Therapeutics (SLNO) deregister?

It deregistered a resale registration for 3,000,000 shares of common stock. The post-effective amendment states the Registration Statement No. 333-275120 is terminated as of May 21, 2026, removing any unsold or unissued securities registered thereunder.

Why was the post-effective amendment filed?

The amendment corrects an administrative filing error and effectuates deregistration after a merger. It notes an earlier May 18, 2026 filing was misfiled as a different form type and removes the resale registration following the Merger Agreement dated April 5, 2026.

Does this filing change the Merger between Soleno and Neurocrine?

No—this amendment reflects post-closing registration housekeeping. It states the Registrant became a wholly owned subsidiary of Neurocrine and terminated the offering; the Merger Agreement (Exhibit 2.1 to the Form 8-K filed April 6, 2026) governs transaction terms.

Will investors receive proceeds from the deregistered resale?

The amendment does not describe proceeds or cash‑flow allocation. It states the Registrant terminated offerings and removed unsold securities from registration; any proceeds treatment or consideration is described in the Merger Agreement and related Form 8-K exhibits.